# R-05 — Musely The Spot Peel — Burst formula

The same 12% hydroquinone as the Body Cream, and this time the number is far less alarming — one application every three to six months, washed off. The problem is different: this is an inflammatory peel sold to treat melasma, and inflammation is what makes melasma come back.

- **Canonical:** https://www.30plusskin.care/reviews/musely-the-spot-peel
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 12 / REV. 2026.08
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## Verdict

- **Stance:** CAUTION — There is a real reason to hesitate. Read the finding before you buy.
- **Weighted score:** 48/100 across 75% of the scoring model
- **Category:** PRESCRIPTION COMPOUNDED / AT-HOME CHEMICAL PEEL
- **Price:** $99 — PER TREATMENT · EVERY 3–6 MONTHS
- **Container size:** NOT PUBLISHED
- **Prescription:** yes
- **Compounded:** yes
- **Assessment basis:** DESK REVIEW
- **Last updated:** 2026-07-24
- **Manufacturer page:** https://www.musely.com/spotpeel

Start with a correction to ourselves. We were hard on the Body Cream for putting 12% hydroquinone on a body-sized area every night, indefinitely. The Spot Peel carries the same headline concentration and almost none of that criticism transfers. This is a single application, left on for eight to twelve hours, washed off, and repeated only every three to six months. Cumulative exposure is roughly two orders of magnitude lower. Short-contact high-concentration is a real dermatological technique, not a shortcut, and putting it behind a prescriber is right.

The problem here is a different one and it is specific to what this product treats. The peel produces redness, a sunburned sensation and visible shedding for seven to ten days. That is an inflammatory event by design. Melasma — the primary indication on the page — is a condition in which inflammation drives rebound pigmentation, and it disproportionately affects Fitzpatrick III to V skin, which is exactly the group in whom aggressive peeling most reliably triggers post-inflammatory hyperpigmentation.

So the mechanism that makes the peel work is also the mechanism that can make the thing you are treating worse. That is a genuine clinical tension. It is manageable with the right patient selection and rigorous sun protection, and it is not mentioned anywhere in the marketing copy.

Then there is the disclosure, which is the weakest of the five products we have assessed. The page says hydroquinone 'up to 12%' — a ceiling, not a dose, so you do not know whether you are buying 4% or 12%. It lists eight actives when the published Burst formula contains five. And it headlines $17 a month for something that is $99 a treatment used two to four times a year.

## Actives, as published

| Active | Concentration | Role | Benchmark | Assessment | Flagged |
| --- | --- | --- | --- | --- | --- |
| Hydroquinone | Up to 12% | Tyrosinase inhibitor — the primary depigmenting agent | 4% is the conventional prescription strength for daily use | The concentration is far more defensible here than in a daily product, because contact time is 8–12 hours every few months rather than nightly. The problem is the phrasing: 'up to' names a ceiling, so a buyer cannot know what they have been prescribed. | yes |
| Tretinoin | 0.01% | Penetration enhancer for the peel | 0.025%–0.1% where tretinoin is the therapeutic agent | The fourth time we have found tretinoin below the trial range in this range — but the most defensible instance. In a single-application peel, tretinoin's job is to increase delivery of the hydroquinone, not to act as a retinoid in its own right. | no |
| Arbutin | 2% | Gentle tyrosinase inhibitor — a glycosylated hydroquinone derivative | 1%–2% is the standard cosmetic range | Correctly dosed. Worth noting that arbutin's distinguishing virtue is that it inhibits tyrosinase without the irritation of free hydroquinone — a virtue largely nullified by combining it with 12% hydroquinone and a retinoid under eight hours of contact. | no |
| Titanium Dioxide | 5% | Opacifier in the base | 15%–25% where it is functioning as a UV filter | At 5% in a wash-off product this is an opacifier, not sun protection. Do not read its presence as any kind of UV cover — which matters, because sun protection after this peel is not optional. | yes |
| Licorice Root Extract | Not stated | Glabridin — mild tyrosinase inhibition and anti-inflammatory | Typically standardised to glabridin content, rarely disclosed | A reasonable supporting inclusion with a mild anti-inflammatory action, which is useful in this context. No concentration published, so treat it as a supporting agent rather than an active. | no |

## Scoring

| Criterion | Weight | Score | Note |
| --- | --- | --- | --- |
| EVIDENCE FOR THE ACTIVE | 30% | 60/100 | Hydroquinone for melasma is grade-A, short-contact peeling is a legitimate technique, and arbutin at 2% has support. Held back because we could find no published trial of this specific protocol — a 12% hydroquinone with tretinoin, self-applied at home for 8–12 hours — and because the rebound-pigmentation risk sits directly in the target population. |
| FORMULATION INTEGRITY | 20% | 55/100 | Coherent as a peel: multiple complementary pigment pathways, an opacified wash-off base, a penetration enhancer used as a penetration enhancer rather than pretending to be a retinoid dose. Marked down because the advertised active list is a superset of the actual formula, and because the one gentle agent is neutralised by what it is mixed with. |
| DISCLOSURE | 15% | 15/100 | The weakest of the five. 'Up to 12%' is a ceiling presented as a specification — the buyer cannot know their own dose. Eight actives are advertised against a five-active published formula. And a $99 per-treatment product used two to four times a year is headlined as $17 a month. |
| TOLERANCE IN USE | 15% | not scorable | Not assessed. Credit where due: unlike the Spot Pill, this page does disclose expected effects — redness, tightness, a sunburned sensation and shedding. That is the right instinct and it should be applied across the range. |
| TEXTURE & WEAR | 10% | not scorable | Not assessed. Requires the product in hand across a full treatment cycle. |
| COST PER APPLICATION | 10% | 50/100 | This is the one product in the range where cost per application is actually computable: $99 a treatment, two to four treatments a year, so roughly $200–$400 annually. Against in-office peels that is genuinely cheap. Marked down for the $17/mo presentation, which obscures a clear and defensible number. |

_A criterion that cannot be assessed from published information is not guessed at. Its weight is removed from the denominator, and the coverage figure above says how much of the model survived._

## Strengths

- Intermittent use makes the 12% concentration far more defensible than the same figure in a daily product.
- Washed off after 8–12 hours, which caps exposure in a way a leave-on cannot.
- Short-contact high-concentration peeling is an established dermatological technique.
- Multiple complementary tyrosinase pathways is a sensible design for melasma specifically.
- The page discloses expected side effects, which the Spot Pill page does not.
- The Day 30 readout is at least consistent with the product's own stated timeline, unlike other claims in this range.
- Cost per application is genuinely computable and genuinely competitive against in-office treatment.

## Weaknesses

- 'Up to 12%' names a ceiling rather than a dose — the buyer cannot know what they were prescribed.
- An inflammatory peel is being sold to treat a condition in which inflammation drives rebound pigmentation.
- No mention anywhere of post-inflammatory hyperpigmentation risk in deeper skin tones.
- Eight actives advertised against a five-active published formula.
- $17/mo headline for a $99 per-treatment product used two to four times a year.
- Titanium dioxide at 5% could be misread as sun protection when post-peel UV avoidance is critical.
- The 80% figure remains an uncontrolled, unblinded, self-reported survey.

## Suits

- Someone with stubborn facial pigmentation who has already tried daily topicals without adequate result.
- Someone with lighter skin, in whom post-inflammatory rebound after peeling is less likely.
- Someone treating discrete sun spots or freckles rather than diffuse melasma — the rebound tension is much weaker for those.
- Someone who can take a week of visible shedding, and who will stay out of the sun and wear high SPF throughout.
- Someone who will ask the prescriber for the exact concentration rather than accepting 'up to 12%'.

## Avoid if

- You are pregnant or breastfeeding. Tretinoin is contraindicated.
- You have Fitzpatrick IV–VI skin and are not being supervised in person — rebound hyperpigmentation is the specific risk and it is difficult to undo.
- You are treating active, inflammatory melasma. Calm it first with gentler agents before considering anything that peels.
- You cannot avoid sun exposure for the following two weeks.
- You have used isotretinoin recently, or have active eczema, rosacea or broken skin on the treatment area.
- You are unwilling to be told the actual concentration you have been prescribed.

## The full assessment

### What it is

The Spot Peel is a compounded prescription chemical peel that you apply at home. The published Burst formula is hydroquinone 12%, tretinoin 0.01%, arbutin 2%, titanium dioxide 5% and licorice root extract. You leave it on for eight to twelve hours, wash it off, and shed for the following week or so. It is repeated every three to six months.

The product page headlines $17 a month. The same page also says 'Starting at $99 Per Treatment', which is the number that actually describes what you are buying.

**RECORD**

| Field | Value |
| --- | --- |
| BRAND | MUSELY |
| PRODUCT | THE SPOT PEEL — BURST FORMULA |
| CLASS | COMPOUNDED PRESCRIPTION PEEL |
| INDICATION | MELASMA · SUN SPOTS · FRECKLES · ACNE MARKS |
| CONTACT TIME | 8–12 HOURS, THEN WASHED OFF |
| FREQUENCY | EVERY 3–6 MONTHS |
| PRICE | $99 PER TREATMENT (SHOWN AS $17/MO) |
| SHEDDING | 7–10 DAYS |

### The same number means something different here

We spent most of our Body Cream review on the fact that 12% hydroquinone is three times the conventional prescription strength, and on the way concentration, treated area and duration stack together in the ochronosis literature. It would be lazy to see the same figure here and repeat the argument. It does not apply in the same way, and we should say so plainly.

**FIG. 1 — HYDROQUINONE APPLICATIONS PER YEAR** — Same concentration, entirely different exposure. The peel is washed off; the body cream is not.

| Item | Value (APPLICATIONS / YEAR) | Note |
| --- | --- | --- |
| THE SPOT PEEL — EVERY 3–6 MONTHS | 4 | Two to four, washed off after 8–12 h |
| CONVENTIONAL 4% COURSE — DAILY, 12 WEEKS | 84 | Time-limited course |
| THE BODY CREAM — NIGHTLY, OPEN-ENDED | 365 | No stopping point in the billing |

_Scale maximum: 365APPLICATIONS / YEAR._

Short-contact therapy — a high concentration for a short, controlled exposure, then removal — is an established technique precisely because it separates potency from cumulative load. Applied two to four times a year and rinsed off, a 12% hydroquinone is a very different proposition from the same percentage applied nightly to both legs forever.

> **WHERE THE REGISTER EARNS ITS KEEP** — Two products from the same company, both at 12% hydroquinone, with materially different verdicts on that specific point. A score that could not distinguish them would not be worth publishing.

### The real tension: peeling a condition that rebounds

The primary indication on the page is melasma. Melasma is a pigmentary disorder that is driven and sustained by inflammation as well as by UV, and it is notoriously prone to rebound. It also disproportionately affects people with Fitzpatrick III to V skin.

This product works by producing a controlled injury. The page is straightforward about the consequences — redness, tightness, a sunburned sensation, and visible shedding for seven to ten days. That is an inflammatory event, and it is the mechanism, not a side effect of it.

> **THE CONFLICT IN ONE SENTENCE** — Aggressive peeling in melanin-rich skin is one of the recognised triggers for post-inflammatory hyperpigmentation — which means the intervention can leave you with more pigment than you started with, in exactly the population most likely to have melasma in the first place.

This is not an argument that nobody should use it. Peels are used for melasma by dermatologists, carefully, with patient selection and priming and rigorous photoprotection. It is an argument that the risk is specific, that it falls unevenly across skin tones, and that a page selling a self-applied peel for melasma should say so. It does not.

If you are treating discrete sun spots or freckles rather than diffuse melasma, this tension is much weaker and the calculus is more favourable. The page does not make that distinction either, and it is the distinction that matters most for deciding whether to buy.

### 'Up to 12%' is not a specification

The product page states hydroquinone 'up to 12%'. We have to be direct about this, because it is the exact construction our own exclusion list rejects: a ceiling is not a result, and it is not a dose either.

A buyer reading 'up to 12%' does not know whether their compounded prescription contains 12%, 8% or 4%. Those are clinically different products with different risk profiles and different expected timelines. The phrasing lets the marketing claim the strongest number while the pharmacy dispenses whatever the prescriber wrote.

There may be a perfectly good clinical reason the concentration varies by patient — that is what individualised compounding is for. That reason is an argument for telling each patient their own number, not for publishing a ceiling and leaving it there.

**WHAT THE PAGE ADVERTISES VS. WHAT THE FORMULA CONTAINS**

| Field | Value |
| --- | --- |
| HYDROQUINONE | ADVERTISED 'UP TO 12%' · IN FORMULA |
| TRETINOIN 0.01% | ADVERTISED · IN FORMULA |
| ARBUTIN 2% | ADVERTISED · IN FORMULA |
| TITANIUM DIOXIDE 5% | ADVERTISED · IN FORMULA |
| LICORICE ROOT | ADVERTISED · IN FORMULA |
| AZELAIC ACID | ADVERTISED · NOT IN BURST |
| KOJIC ACID | ADVERTISED · NOT IN BURST |
| VITAMIN C 1% | ADVERTISED · NOT IN BURST |

This is the same pattern we found on the KP Cream: a product page listing the union of every active across every variant, presented as though it describes the thing in the box. Three of the eight advertised actives are absent from the published Burst formula. And vitamin C at 1% would not have been doing anything anyway — ascorbic acid needs roughly ten times that, at low pH, to function.

### The price is fine. The way it is shown is not.

At $99 a treatment, used two to four times a year, this costs roughly $200 to $400 annually. Against in-office chemical peels that is a genuinely competitive number, and it is the one product in this range where cost per application can actually be calculated, because both the price and the frequency are published.

Which makes the $17 a month headline all the more frustrating. Dividing $99 across six months produces a figure that looks like a cheap monthly subscription for something that is neither cheap nor monthly. The honest presentation — $99 per treatment, two to four times a year — is a better offer than the one being advertised, and it is a shame the page does not lead with it.

### Titanium dioxide is not sunscreen

Titanium dioxide at 5% appears in the formula. In a wash-off treatment applied overnight it is functioning as an opacifier for the base, not as a UV filter — mineral sunscreens run at fifteen to twenty-five percent, and they are not rinsed off before the sun comes up.

We flag it because photoprotection after this treatment is not optional. Freshly peeled skin treated with a depigmenting agent is at its most vulnerable to exactly the UV-driven pigmentation you paid to remove. Anyone who sees a familiar sunscreen ingredient on the list and relaxes has been misled by a coincidence.

### The 80% figure

Eighty percent of patients reported visible improvement by day 30, from 13,321 patients logging results at days 7, 30 and 60. The design criticism is the same as every other figure in this range — self-reported, uncontrolled, unblinded, assessed by the purchaser.

In fairness, this is the one instance where the timepoint is not also a problem. The product's own materials say results can take up to thirty days and that shedding runs seven to ten, so a day-30 readout sits sensibly within the product's stated course. That is more internally consistent than a 90% figure at day 30 for a twelve-week oral course, or a 91% figure at day 30 for a retinoid the same page says takes six to eight weeks.

### If you are going to use it

- Ask the prescriber for your actual hydroquinone concentration. 'Up to 12%' is not an answer; a number is.
- Tell them your Fitzpatrick type and ask directly about rebound pigmentation risk before you apply anything.
- If you are treating melasma rather than discrete spots, ask whether a peel is the right first move at all.
- Clear your calendar. Seven to ten days of visible shedding is the expected course, not a complication.
- Stay out of the sun and wear a real sunscreen — a proper SPF 50, not the titanium dioxide in the peel.
- Do not exfoliate, scrub or pick during shedding. That is how a controlled peel becomes an uncontrolled injury.
- Photograph the area under fixed lighting before and at thirty days. Pigment changes are gradual and memory is unreliable.
- Do not use it if there is any chance you are pregnant.

### Where we stand

The pharmacology here is more defensible than the headline concentration suggests, and we have said so at length because it would have been easy and wrong to recycle the Body Cream argument. Intermittent, washed-off, prescriber-gated short-contact therapy is a legitimate model, and the annual cost is fair.

What holds it at caution is the combination of a specific clinical risk that falls unevenly across skin tones and goes entirely unmentioned, with the weakest disclosure we have assessed: a concentration published as a ceiling, an ingredient list that overstates the formula by three actives, and a price presented in a unit the product is not sold in.

A buyer with lighter skin treating a few sun spots is looking at a reasonable product with a fair price. A buyer with deeper skin treating diffuse melasma is looking at something that could plausibly make their complaint worse, and nothing on the page helps them tell which of those two people they are.

## Where to buy

| Retailer | Price | Link | Note | Commission-bearing |
| --- | --- | --- | --- | --- |
| Musely | $99 / treatment | https://www.musely.com/spotpeel?utm_source=30plusskin&utm_medium=affiliate&utm_campaign=review&utm_content=musely-the-spot-peel&utm_term=markdown | Advertised as $17/mo. Consultation required. Single-use treatment. | yes — affiliate link |

A one-day treatment repeated every 3–6 months, not a monthly product. Read the rebound-pigmentation section above if your skin tone is Fitzpatrick III or deeper.

## Sources

- [Musely — The Spot Peel product page](https://www.musely.com/spotpeel) — Pricing, the 'up to 12%' phrasing, the eight advertised actives, the 80% self-report figure, directions and disclosed side effects.
- [Musely Help Centre — formulas for The Spot Peel](https://support.musely.com/hc/en-us/articles/1500001583481-What-are-the-formulas-for-The-Spot-Peel) — Source of the published Burst formula: hydroquinone 12%, tretinoin 0.01%, licorice root, arbutin 2%, titanium dioxide 5%.
- [Musely Help Centre — The Spot Peel: how to use and expectations](https://support.musely.com/hc/en-us/articles/16610900949655-The-Spot-Peel-How-to-Use-Expectations) — Single-day application, 8–12 hour contact time, repeat every 3–6 months, shedding for 7–10 days.
- [Alpha-arbutin: mechanism, concentration range and suitability for melanin-rich skin](https://shop.skinaa.com/blogs/news/alpha-arbutin-dark-spots-pigmentation-research) — Arbutin at 1–2% does not release free hydroquinone at cosmetic concentrations, and is favoured in Fitzpatrick IV–VI precisely because it avoids the irritation that triggers rebound pigmentation.
- [Topical alpha-arbutin with sunscreen in facial melasma — prospective interventional study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822242/) — Context for arbutin's role and for the centrality of photoprotection in melasma management.

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_EVERY FIGURE RESOLVES TO A RECORD. NO NUMBER ON THIS SITE IS AUTHORED BY US._